J
Joachim von Pawel
Researcher at University of Texas MD Anderson Cancer Center
Publications - 144
Citations - 27028
Joachim von Pawel is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 52, co-authored 142 publications receiving 25012 citations.
Papers
More filters
Journal ArticleDOI
Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer
Joachim von Pawel,Jimmie H. Harvey,David R. Spigel,Mircea Dediu,Martin Reck,Cristina L. Cebotaru,Robin Humphreys,Matthew Joseph Gribbin,N. L. Fox,D. Ross Camidge +9 more
TL;DR: This study showed no clinical benefit from adding mapatumumab to carboplatin and paclitaxel in unselected patients with NSCLC, and the combination was generally well tolerated.
Journal ArticleDOI
Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.
Willem W. ten Bokkel Huinink,Bengt Bergman,Assad Chemaissani,Wolfgang Dornoff,Peter Drings,Piikko-Liisa Kellokumpu-Lehtinen,Kari Liippo,Karin Mattson,Joachim von Pawel,Sergio Ricci,Christer Sederholm,Rolf A. Stahel,Gunnar Wagenius,N. v. Walree,Christian Manegold +14 more
TL;DR: It is shown that single-agent gemcitabine is an active and effective therapy for patients with non-resectable, locally advanced or metastatic non-small cell lung cancer and good performance status, and that it is better tolerated than the combination cisplatin/ etoposide.
Journal ArticleDOI
Phase III Trial Comparing Vinflunine With Docetaxel in Second-Line Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy
Maciej Krzakowski,Rodryg Ramlau,Jacek Jassem,Aleksandra Szczesna,Petr Zatloukal,Joachim von Pawel,X. Sun,Jaafar Bennouna,Armando Santoro,Bonne Biesma,François M. Delgado,Yacine Salhi,Nathalie Vaissiere,Olfred Hansen,Eng Huat Tan,Elisabeth Quoix,Pilar Garrido,Jean-Yves Douillard +17 more
TL;DR: This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel, and the overall toxicity profile of VFL was manageable, suggesting it may be another option in the second-line treatment of patients with advanced NSCLC.
Journal ArticleDOI
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial
Nasser H. Hanna,Rolf Kaiser,Rolf Kaiser,Richard Sullivan,Osvaldo Rudy Aren,Myung-Ju Ahn,Beatrice Tiangco,Isabelle Voccia,Joachim von Pawel,Vladimir Kovcin,Jason Agulnik,Birgit Gaschler-Markefski,José Barrueco,Patricia Sikken,Charles Schloss,Joo Hang Kim +15 more
TL;DR: Although recruitment stopped prematurely, combining nintedanib with pemetrexed significantly prolonged PFS in patients with advanced non-squamous NSCLC after first-line chemotherapy, with a manageable safety profile.
Journal ArticleDOI
Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer.
Stefan Holdenrieder,Joachim von Pawel,Elke Dankelmann,Thomas Duell,Bernhard Faderl,Andreas Markus,Maria Siakavara,Horst Wagner,Knut Feldmann,Harald Hoffmann,Hannelore Raith,Dorothea Nagel,Petra Stieber +12 more
TL;DR: Nucleosomes and CYFRA 21-1 showed to be valuable for the individual management of patients with recurrent NSCLC and combination model achieved sensitivities of 19% at 100% specificity and of 52% at 88% specificity.